Inhibrx, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 78.71 million compared to USD 48.92 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.12 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.7 USD | -2.58% |
|
+3.57% | -61.32% |
04/06 | Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing | MT |
31/05 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
1st Jan change | Capi. | |
---|---|---|
-61.32% | 1.79B | |
+16.55% | 122B | |
+21.60% | 116B | |
+22.18% | 27.03B | |
-21.44% | 20.36B | |
-16.89% | 16.43B | |
-17.91% | 15.91B | |
-44.74% | 15.6B | |
+61.83% | 14.94B | |
+3.54% | 13.59B |
- Stock Market
- Equities
- INBX Stock
- News Inhibrx, Inc.
- Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024